Abstract-The antihypertensive agent omapatrilat represents a novel approach to antihypertensive therapy, namely vasopeptidase inhibition. Omapatrilat (BMS-186716) concomitantly inhibits neutral endopeptidase and angiotensinconverting enzyme, leading to protection from degradation of natriuretic and other hypotensive peptides in addition to interruption of the renin-angiotensin system. Although the potency of omapatrilat on reduction of blood pressure has been reported, its effects on resistance artery structure and function were unknown. We tested omapatrilat in stroke-prone spontaneously hypertensive rats (SHRSP), a malignant model of hypertension, with the hypothesis that it would improve the structure and endothelial function of mesenteric resistance arteries. Ten-week-old SHRSP were treated orally for 10 weeks with omapatrilat (40 mg/kg per day). Mesenteric arteries (lumen Ͻ300 m) were studied on a pressurized myograph. After 10 weeks, untreated SHRSP had a systolic blood pressure of 230Ϯ2 mm Hg that was significantly reduced (PϽ0.05) by omapatrilat (145Ϯ3 mm Hg). Omapatrilat treatment improved endotheliumdependent relaxation of resistance arteries as elicited by acetylcholine (10 Ϫ5 mol/L) but had no significant effect on endothelium-independent relaxation produced by a nitric oxide donor (sodium nitroprusside). This suggested that there existed endothelial dysfunction in SHRSP that was corrected by vasopeptidase inhibition, probably in part caused by the potent blood pressure-lowering effect of omapatrilat. Media width and media/lumen ratio were significantly decreased (PϽ0.05) by omapatrilat, and a trend (Pϭ0.07) to increase lumen diameter was observed. Vascular stiffness (slope of the elastic modulus versus stress curve) was unaltered by omapatrilat. In conclusion, omapatrilat, acting as a potent antihypertensive agent, may improve structure and endothelial function of resistance arteries in SHRSP, a severe form of genetic hypertension. Key Words: hypertension, malignant Ⅲ vasculature Ⅲ angiotensin-converting enzyme Ⅲ natriuretic peptides Ⅲ rats, stroke-prone SHR Ⅲ remodeling A novel basis for treatment of hypertension has recently been introduced in which a single molecule may moderate multiple physiological systems. One example of this treatment rationale is the vasopeptidase inhibitor omapatrilat (BMS-186716), a mercaptoacetyl-based, fused heterocyclic dipeptide mimetic, 1 which is a potent inhibitor of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). These enzymes are involved in the metabolism of several peptides that modulate blood pressure and sodium homeostasis, including angiotensin II, atrial natriuretic peptide (ANP), and bradykinin.
A novel basis for treatment of hypertension has recently been introduced in which a single molecule may moderate multiple physiological systems. One example of this treatment rationale is the vasopeptidase inhibitor omapatrilat (BMS-186716), a mercaptoacetyl-based, fused heterocyclic dipeptide mimetic, 1 which is a potent inhibitor of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). These enzymes are involved in the metabolism of several peptides that modulate blood pressure and sodium homeostasis, including angiotensin II, atrial natriuretic peptide (ANP), and bradykinin.
The stroke-prone hypertensive rat (SHRSP) model is a genetic model of malignant hypertension with an angiotensin-dependent component. ACE inhibitors significantly reduced systolic blood pressure in this model whether administered peripherally 2 or centrally. 3 Indeed, the conversion of angiotensin I to angiotensin II was markedly augmented in both spontaneously hypertensive rats (SHR) and SHRSP compared with Wistar-Kyoto rats. 4 ACE also inactivates bradykinin 5 and therefore ACE inhibition, by contributing to the accumulation of bradykinin, may facilitate the improved cardiac function 6 and the vasodilatory effects of this hormone that otherwise appear normal in SHRSP. 7 The effects of NEP inhibition in SHRSP are less well studied, and the role that natriuretic peptides may play in the pathophysiology of SHRSP is unclear. Secretion of ANP from the heart is increased in SHR and SHRSP, 8, 9 as is gene expression of guanylate cyclase-A receptor in the kidney. 10 However, in deoxycorticosterone acetate (DOCA)-salt but not SHR, NEP inhibition increased diuresis and natriuresis as well as urinary cGMP, ANP, and bradykinin. 11 Nonetheless, the blood pressure-lowering effect of ACE inhibition was potentiated in SHR but not DOCA-salt rats by concomitant blockade of both enzymes. 11, 12 We tested the hypothesis that vasopeptidase inhibition would have potent blood pressure-reducing effects and would significantly improve endothelial function and structure of resistance arteries in SHRSP. To assess endothelial function, we evaluated vasodilatory responses to acetylcholine, which are impaired in SHR. 13 
Methods

Animals
The study was conducted according to recommendations from the Animal Care Committee of the Clinical Research Institute of Montreal and the Canadian Council of Animal Care. Male SHRSP were obtained from a colony originally acquired from the National Institutes of Health and maintained locally. They were housed at 22°C and 60% humidity under a 12-hour light/dark cycle. Starting at 10 weeks old, rats were fed powdered diets (Purina Chow) containing omapatrilat (40 mg/kg per day, a dose that exerts a blood pressure-lowering effect equivalent to that of 10 mg/kg per day enalapril). Omapatrilat was kindly provided by Dr James R. Powell from Bristol-Myers Squibb.
Systolic blood pressure was measured biweekly by the tail-cuff method after rats were warmed and under slight restraint and recorded on a model 7 polygraph fitted with a 7-P8 preamplifier and PCPB photoelectric pulse sensor (Grass Instruments Co). The average of 3 pressure readings was obtained.
Preparation of Resistance Arteries
Rats were killed at 20 weeks of age by decapitation, and the mesenteric vasculature was dissected. Superior mesenteric arteries were taken from the part of the mesenteric vascular bed that feeds the jejunum 8 to 10 cm distal to the pylorus and placed in cold physiological salt solution (PSS) of the following composition: NaCl 120 mmol/L, NaHCO 3 A third-order branch of the mesenteric arterial tree (Ϸ2 mm in length) was carefully dissected 1 mm from the intestine and cleaned of all adherent connective tissue under a dissecting microscope. The arterial segments were mounted in a pressurized myograph chamber as previously described 14 and slipped onto 2 glass microcannulas. One cannula was adjustable and the other was fixed. Both ends of the arterial segment were secured to the microcannulas with nylon ties. The axial length of the arterial segment was adjusted by carefully positioning the cannula until vascular walls were parallel without any stretch. Intraluminal pressure was set to 45 mm Hg with a Servo-controlled pump. Vessels were then equilibrated for 1 hour in PSS that was bubbled with 95% air and 5% CO 2 to give a pH of 7.4 to 7.45 and heated to 37°C.
Endothelial Function Studies
Endothelium-dependent relaxation was assessed by measuring the dilatory response to cumulative doses of acetylcholine (10
mol/L) of resistance arteries precontracted with norepinephrine (10 Ϫ5 mol/L). Endothelium-independent relaxation was assessed by measuring the dilatory response to cumulative doses of sodium nitroprusside (10 Ϫ7 to 10 Ϫ4 mol/L) of small arteries precontracted with norepinephrine (10 Ϫ5 mol/L).
Vascular Morphology Studies
To eliminate myogenic tone, mesenteric resistance arteries were deactivated by extraluminal perfusion with Ca 2ϩ -free PSS containing 10 mmol/L EGTA for 30 minutes. Lumen and media dimensions were measured while the intraluminal pressure was maintained at 45 mm Hg.
Vascular Mechanics
Arterial wall stiffness was assessed by increasing intraluminal pressure stepwise up to 140 mm Hg, as previously described, 15 and measuring media thickness and lumen diameter at 5 points along the vessel wall. The initial diameter was measured at 3 mm Hg unless the vessel collapsed. In these cases, intraluminal pressure-lumen diameter data (from 10 to 140 mm Hg) were fit to a third-order polynomial equation, and lumen diameter was estimated. 
Calculation of Morphology and Mechanics
Data Analysis
Data are presented as meanϮSEM. Nonrepeated measurements were compared by means of the unpaired Student's t test. Repeated data including mechanics were compared by means of ANOVA for repeated measures. Interaction means were analyzed for "simple main effects" with the use of a Student's t test for unpaired data. A level of PϽ0.05 was considered significant.
Results
Body Weight and Blood Pressure
Untreated SHRSP weighed significantly less (305Ϯ4 g) compared with SHRSP treated with omapatrilat (319Ϯ2 g) (PϽ0.01), a difference that developed progressively since the beginning of treatment, as we have found in previous studies with effective antihypertensive treatment of hypertensive rats. After 2 weeks of treatment, systolic blood pressure was significantly reduced by omapatrilat, which was maintained for the duration of the study (Figure 1 ).
Relaxatory Function of Mesenteric Resistance Arteries
The vasodilatory response to acetylcholine, which is a measure of endothelium-dependent relaxation, was assessed. As depicted in the left panel of Figure 2 , acetylcholine (10 Ϫ5 mol/L) produced a 64.0Ϯ14.0% relaxatory response in mesenteric resistance arteries from untreated SHRSP that was improved by omapatrilat treatment (101.5Ϯ2.5%; PϽ0.05). Omapatrilat had no significant effect on endotheliumindependent relaxation (Figure 2 ) produced by a nitric oxide donor (sodium nitroprusside), which, at the highest dose of 10 Ϫ4 mol/L, was 73.5Ϯ6.6% and 76.8Ϯ14.1% for untreated and omapatrilat-treated SHRSP, respectively.
Morphology and Mechanics of Mesenteric Resistance Arteries
Omapatrilat resulted in a tendency to increase lumen diameter (Pϭ0.07) and decrease media width (from 17.5Ϯ0.9% to 15.0Ϯ0.6%, PϽ0.05) and media/lumen ratio (from 9.7Ϯ0.1% to 6.6Ϯ0.6%, PϽ0.05) in mesenteric resistance arteries from SHRSP ( Figure 3) . Stiffness of resistance artery wall components (slope of the elastic modulus versus stress curve) was unaltered by omapatrilat ( Figure 4 ).
Discussion
Simultaneous inhibition of NEP and ACE with omapatrilat had potent effects on systolic blood pressure in SHRSP, reducing it by Ϸ85 mm Hg. The novel finding, however, is that omapatrilat also significantly improved endothelial relaxatory function and decreased media width and media/ lumen ratio of mesenteric resistance arteries from SHRSP.
In this study, omapatrilat reduced blood pressure significantly in SHRSP. Indeed, vasopeptidase inhibition with omapatrilat appears to have potent antihypertensive effects in various rat models of hypertension 17, 18 as well as in normotensive 19 and hypertensive 20 humans. In general, ACE inhibition is effective antihypertensive therapy in high-renin and normal-renin models such as renovascular rats and SHR, respectively, but less so in low-renin models such as DOCAsalt rats. 18 On the contrary, NEP inhibitors are only effective in the latter, in which NEP inhibition increased diuresis and natriuresis as well as urinary cGMP, ANP, and bradykinin but failed to do so in SHR. 11 Nevertheless, despite its lack of efficacy alone in SHR, NEP inhibition synergistically potentiated the blood pressure-lowering effect of ACE inhibition in SHR but not in DOCA-salt rats. 11, 12 The mechanism of action of omapatrilat is dichotomous, in which one arm is interruption of the renin-angiotensin system and the other is accumulation of natriuretic factors and vasodilatory peptides, such as bradykinin. 21 Since both NEP and ACE inactivate bradykinin, 5 perhaps combined NEP/ACE inhibition results in more complete protection of bradykinin, thereby explaining the potent effect of omapatrilat on blood pressure.
Vasopeptidase inhibition improved acetylcholine-induced, endothelium-dependent relaxation in mesenteric resistance arteries from SHRSP. The mechanisms involved in this improvement are unclear, although significant reduction in blood pressure probably plays a role. Blocking the actions of angiotensin II certainly has been shown to improve endothelial function in SHRSP, either by AT 1 -angiotensin receptor blockade 22 or ACE inhibition. 23, 24 NEP inhibition, through enhanced natriuretic peptide and bradykinin availability, may also contribute to the improvement of vasodilatory response to acetylcholine. For example, C-type natriuretic peptide (CNP) acts as an endothelium-derived relaxatory peptide 25 and has been shown to mediate coronary vasodilation. 26 Exogenous bradykinin has also been shown to potentiate acetylcholine-induced relaxations in arterial rings from SHR in the presence of ACE inhibition, 27 and it is possible that increases in endogenous bradykinin by vasopeptidase inhibition may be acting similarly to improve endotheliumdependent relaxation.
With respect to vascular remodeling, it is very well known that ACE inhibition or antagonism of AT 1 -angiotensin receptors prevents or regresses changes in resistance artery structure. As depicted in Figure 5 , many antihypertensive agents including ACE inhibitors fosinopril 28 and enalapril 29 as well as AT 1 -receptor antagonists irbesartan 28 and losartan 30 correct media/lumen ratio in a manner that correlates with the blood pressure-lowering effect of each agent. Omapatrilat also dramatically reduced media/lumen ratio in accordance with its remarkable effect on blood pressure, more so than other inhibitors of the renin-angiotensin system. One possible reason for the extended effect of omapatrilat on media/lumen ratio may be due to its distinctively potent effect on blood pressure as discussed above and may be at least in part attributed to NEP inhibition. Admittedly, NEP inhibition may result in decreased degradation of endothelin, as evidenced by an increase in circulating endothelin levels, 31 and endothelin has been implicated in the hypertrophic remodeling typically detected in SHRSP. 32, 33 In an experimental model of pulmonary hypertension, NEP inhibition with the use of candoxatrilat nonetheless reduced pulmonary vascular remodeling. 34 ANP has also been shown in vivo to inhibit hypertrophy of rat aortic smooth muscle cells. 35 Marumo et al 36 reported that cytokine-induced nitric oxide production was significantly increased by ANP, brain natriuretic peptide, and CNP in rat aortic smooth muscle cells, accompanied by increased inducible nitric oxide synthase messenger levels. The resulting increase in nitric oxide may prevent vascular remodeling by the nature of its antigrowth effects. Moreover, CNP, which is produced also by vascular endothelial cells, exerts growthinhibitory actions and is able to antagonize the growthpromoting effect of angiotensin II. 37 The present findings combined with these purported antigrowth effects of natriuretic peptides suggest that increases in the hypertrophic peptide endothelin by NEP inhibition may be overcome by the antigrowth effects of natriuretic peptides. It should be noted that in contrast to small artery structure, which clearly appears to be corrected in rats in correlation with the degree of blood pressure lowering ( Figure 5) , 38, 39 when antihypertensive agents correct endothelial dysfunction in hypertensive rats, this occurs to a maximum degree whenever structure is improved independent of the degree of blood pressure normalization. This suggests that in rats, correction of endothelial dysfunction is found more easily and completely than for arterial structure, 28 -30,40 which is somewhat different from human studies. 41 In conclusion, this report provides further evidence that vasopeptidase inhibition in SHRSP results in potent antihypertensive effects and moreover produces significant vascular protection in the form of improved endothelial function and reduction of media/lumen ratio of resistance arteries. These actions of omapatrilat may confer protection against the extensive end-organ damage characteristic of severe or malignant hypertension. 
